Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)

This study is testing a new drug combination — sacituzumab tirumotecan plus tagitanlimab — in men with an aggressive, hard-to-treat form of prostate cancer called aggressive variant prostate cancer (AVPC) or neuroendocrine prostate cancer (NEPC) that has stopped responding to hormone-blocking therapies. **You may be eligible if...** - You are 18 or older - You have been diagnosed with aggressive variant or neuroendocrine prostate cancer - You have already tried one or two second-generation hormone therapies (like enzalutamide or abiraterone) - Your cancer has shown signs of getting worse in the past 6 months based on PSA levels or imaging **You may NOT be eligible if...** - You have had more than two prior lines of chemotherapy for prostate cancer (beyond docetaxel) - You have active, uncontrolled infections or serious organ problems - You have active brain metastases - You are on certain blood-thinning medications with uncontrolled clotting issues Talk to your doctor to see if this trial is right for you.